Zhengxiang Han1, Xuan Sun1, Guan Jiang2, Xiuping Du1. 1. Department of Oncology , Affiliated Hospital of Xuzhou Medical College, Xuzhou, Jiangsu 221000, P.R. China. 2. Department of Dermatology, Affiliated Hospital of Xuzhou Medical College, Xuzhou, Jiangsu 221000, P.R. China.
Abstract
OBJECTIVE: To explore the efficacy and safety of thalidomide for the treatment of delayed vomiting, induced by chemotherapy in cancer patients. STUDY DESIGN: Randomized, double-blind controlled study. PLACE AND DURATION OF STUDY: The Oncology Department of Affiliated Hospital of Xuzhou Medical University, Jiangsu Xuzhou, China, from January 2012 to January 2014. METHODOLOGY: A total of 78 cancer patients, who had delayed vomiting observed from 24 hours to 1 week after chemotherapy, were included in the study. Patients were divided in a treatment group (40 patients, 51.28%) and a control group (38 patients, 48.71%). The treatment group received thalidomide at an oral dose of 100 mg per night; 50 mg was added daily up to a dose of 200 mg per night, if the curative effect was suboptimal and the medicine was tolerated. Both the treatment and the control groups received a drip of 10 mg azasetron 30 minutes before chemotherapy. The control group only proportions of antiemetic effects and adverse reactions were compared using the c2 test. Antiemetic effects and adverse reactions were assessed from Odds Ratios (OR) with 95% Confidence Intervals(95% CI). RESULTS: The effective control rate of delayed vomiting in the treatment group was significantly higher than that in the control group (c2=5.174, p=0.023). No significant difference was found between the two groups in other adverse effects of chemotherapy. Karnofsky scores or the overall self-evaluation of the patients (p>0.05). CONCLUSION:Thalidomide can effectively control the delayed vomiting of cancer patients receivingchemotherapy and the adverse reactions of the agent can be tolerated.
RCT Entities:
OBJECTIVE: To explore the efficacy and safety of thalidomide for the treatment of delayed vomiting, induced by chemotherapy in cancerpatients. STUDY DESIGN: Randomized, double-blind controlled study. PLACE AND DURATION OF STUDY: The Oncology Department of Affiliated Hospital of Xuzhou Medical University, Jiangsu Xuzhou, China, from January 2012 to January 2014. METHODOLOGY: A total of 78 cancerpatients, who had delayed vomiting observed from 24 hours to 1 week after chemotherapy, were included in the study. Patients were divided in a treatment group (40 patients, 51.28%) and a control group (38 patients, 48.71%). The treatment group received thalidomide at an oral dose of 100 mg per night; 50 mg was added daily up to a dose of 200 mg per night, if the curative effect was suboptimal and the medicine was tolerated. Both the treatment and the control groups received a drip of 10 mg azasetron 30 minutes before chemotherapy. The control group only proportions of antiemetic effects and adverse reactions were compared using the c2 test. Antiemetic effects and adverse reactions were assessed from Odds Ratios (OR) with 95% Confidence Intervals(95% CI). RESULTS: The effective control rate of delayed vomiting in the treatment group was significantly higher than that in the control group (c2=5.174, p=0.023). No significant difference was found between the two groups in other adverse effects of chemotherapy. Karnofsky scores or the overall self-evaluation of the patients (p>0.05). CONCLUSION:Thalidomide can effectively control the delayed vomiting of cancerpatients receiving chemotherapy and the adverse reactions of the agent can be tolerated.